These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 9119120

  • 1. Viral Safety and Evaluation of Viral Clearance from Biopharmaceutical Products. Proceedings of a meeting. Bethesda, Maryland, USA, June 14-16, 1995.
    Dev Biol Stand; 1996; 88():1-342. PubMed ID: 9119120
    [No Abstract] [Full Text] [Related]

  • 2. International scientific conference on viral safety and evaluation of viral clearance from biopharmaceutical products.14-16 June 1995, Bethesda, MD, USA.
    Sanhueza S.
    Vaccine; 1996 Feb; 14(3):244-6. PubMed ID: 8920707
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Strategies for the validation of viral inactivation in biologic products.
    Aronson DL.
    Prog Clin Biol Res; 1990 Feb; 324():137-49. PubMed ID: 2408050
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Issues related to harmonization of testing requirements for viral safety.
    Hayakawa T.
    Dev Biol Stand; 1996 Feb; 88():15-8. PubMed ID: 9119129
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification and remediation of a cell culture virus contamination.
    Jones N.
    PDA J Pharm Sci Technol; 2011 Feb; 65(6):615. PubMed ID: 22294585
    [Abstract] [Full Text] [Related]

  • 11. Validation of biopharmaceutical purification processes for virus clearance evaluation.
    Darling A.
    Mol Biotechnol; 2002 May; 21(1):57-83. PubMed ID: 11989660
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. FDA post-approval expectations for adventitious virus contamination prevention.
    Friedman RL.
    PDA J Pharm Sci Technol; 2011 May; 65(6):698-712. PubMed ID: 22294604
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Introduction to the issues: viral vectors and potential problems in their use.
    Klinman DM.
    Dev Biol Stand; 1992 May; 76():299-300. PubMed ID: 1478347
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Theoretical considerations on viral inactivation or elimination.
    Willkommen H, Löwer J.
    Dev Biol Stand; 1993 May; 81():109-16. PubMed ID: 8174793
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.